Skip to main content
Equibles
CDNA logo

CDNA · CareDx, Inc.

Track CDNA — free

Use CDNA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about CDNA

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$46.99 +0.48 (+1.03%) At close · Aug 20
Market Cap
$2.43B
Shares
51.73M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$46.99 Open$45.90 Day$45.33–47.85 52W close$12.17–47.85 Avg vol 30d1.2M Short int6.1M · 11.9% float · 4.3d Short vol67% Last earningsJul 30, 2026 DataJan 2020–Aug 2026 Filing10-Q · Jul 30

Up next

Next earnings call
Oct 30, 2026 Est · unconfirmed · in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jul 30, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Buy
      SellHoldBuy
      Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
      Market backdrop VIX 14.9 · calm Equity put/call 0.52
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +103%
      above
      Price vs 50-day avg +34%
      above
      RSI (14) 68
      neutral
      MACD trend Negative
      52-week position 98%
      near high
      Volume (OBV) Confirms
      volume backs price
      Momentum
      relative strength
      Very Strong
      1-month return +25%
      trailing
      6-month return +150%
      trailing
      YTD return +149%
      this year
      Relative strength +139%
      vs S&P · 6-mo
      Sentiment
      smart money
      Bullish
      Trend (MA cross) No cross
      50d $35 › 200d $23 — 50d above 200d
      Institutional flow Accumulating
      +18% holders QoQ · +54 funds added
      Insider flow Distributing
      Net -$3.0M over 90 days · 100% sells
      Short interest Falling
      11.86% of float · ▼ -0.8% MoM · 4.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      225 holders — near 3-yr high, broad support
      Squeeze score 74
      high risk · 0–100
      Fundamentals
      Excellent
      Revenue growth +19%
      Y/Y
      Gross margin 169%
      expanding
      EPS growth −143%
      Y/Y
      Free cash flow $40.0M
      Valuation P/E 22.7
      below peers
      Buyback $100.0M
      authorized
      Balance sheet $65.4M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 72%
      annualized · 1-yr
      Max drawdown −24%
      past year
      ATR 4.6%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 3 of last 3
      Latest guidance · from the 8-K filed Jul 30, 2026
      Revenue · full year 2026 Initiated $490M – $500M
      prior FY $379.81M midpoint +30.3% Y/Y
      Adjusted EBITDA · full year 2026 Non-GAAP Initiated $66M – $78M
      Prior guidance period ended · from the 8-K filed Nov 4, 2025
      Revenue · full year 2025 $372M – $376M
      Adjusted EBITDA · full year 2025 $35M – $39M
      Guided vs delivered · last 3 settled
      Revenue full year 2025
      guided $372M – $376M
      $379.81M Beat +1.6%
      Full-year '24 revenue full-year '24
      guided $260M – $274M
      $333.79M Beat +25.0%
      Full year 2023 revenue full year 2023
      guided $274M – $278M
      $280.32M Beat +1.6%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 3
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +103% Bullish
      Price vs 50-day avg
      +34% Bullish
      RSI (14)
      68 Neutral
      MACD trend
      Negative Bearish
      52-week position
      98% Bullish
      Volume (OBV)
      Confirms Neutral
      Market signals — smart money & positioning
      Bullish · 3 of 6
      Trend (MA cross) No cross
      50d $35 › 200d $23 — 50d above 200d
      Institutional flow Accumulating
      +18% holders QoQ · +54 funds added
      Insider flow Distributing
      Net -$3.0M over 90 days · 100% sells
      Short interest Falling
      11.86% of float · ▼ -0.8% MoM · 4.3 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      225 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $12 Now $47 · 98% Range high $48
      vs 200-day avg +103% vs 50-day avg +34%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      GAAP → non-GAAP reconciliation
      GAAP GAAP net income (loss) 110.64M
      -112.97M Gain on sale of lab products business
      +10.65M Stock-based compensation expense
      +11.08M Business development and portfolio optimization expense*
      +529K Acquisition related-amortization of purchased intangibles
      +0K Acquisition related fees and expenses
      +0K Change in estimated fair value of contingent consideration
      +54K Tax effect related to amortization of purchased intangibles
      +0K Transformational initiative costs
      +0K Restructuring costs
      +0K Litigation settlement expense
      -1.74M Interest income
      +3.83M Income tax expense (income)
      +2.29M Depreciation expense
      +440K Other expense (income), net
      = Adjusted EBITDA 24.8M
      Adjusted EBITDA margin non-GAAP 19% Three Months Ended June 30, 2026 —
      Non-GAAP basic net income per share non-GAAP $0.39 Three Months Ended June 30, 2026 —
      Non-GAAP diluted net income per share non-GAAP $0.37 Three Months Ended June 30, 2026 —
      Average share repurchase price $15.79 the fourth quarter —
      Share repurchases 12M the fourth quarter —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Diagnostics & Research — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      CDNA
      CareDx, Inc.
      this stock
      		$2.43B +149.4% +18.9% 22.7 11.9%
      TMO
      Thermo Fisher Scientific Inc.
      		 $231.21B +8.3% +14.5% 33.6 1.3%
      DHR
      Danaher Corp /De/
      		 $147.41B -5.7% +8.5% 37.2 1.7%
      NTRA
      Natera, Inc.
      		 $46.86B +41.8% -2.8% — 3.0%
      IDXX
      Idexx Laboratories Inc /De
      		 $44.29B -19.3% +10.4% 39.5 2.4%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      225
      % held
      102.0%
      Net QoQ
      +219.7K sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      231
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      6.1M
      Days to cover
      4.3d
      Change
      -52.1K sh
      View
      Short Volume
      Short vol %
      67%
      As of
      Aug 20, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      348
      Value
      $13.3K
      As of
      Jul 31, 2026
      View
      Off-Exchange
      Off-exchange %
      45.7%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$3.0M
      Buyers / Sellers
      0 / 2
      Buyers Sellers
      View
      Congressional Trades Sell
      Member
      Daniel Goldman
      Amount
      $1.0K–$15.0K
      Traded
      Mar 6, 2023
      View
      Financials
      Financials
      Revenue (FY)
      $379.8M
      Net income (FY)
      $-21.4M
      EPS diluted
      $-0.40
      View
      Buybacks
      Authorized
      $100.0M
      Remaining
      $0
      Spent Remaining
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Jul 30, 2026
      This year
      14
      View
      Proposed Sales
      Value
      $423.1K
      Shares
      9.1K
      Filed
      Aug 17, 2026
      View
      Earnings & Events
      Earnings Calls
      Last call
      Jul 30, 2026
      View
      Investor Relations
      Latest news
      CareDx Announces Inducement Grant…
      Published
      Aug 7, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      CDNA -0.8% +24.9% +150.5% +7.5% +149.4%
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY +1.1% +21.6% +139.3% +5.4% +137.6%

      Capital returns

      Buyback program · as of Jun 30, 2026
      Authorized
      $100.00M
      Spent (derived)
      $100.00M
      Remaining
      $0
      Spent Remaining

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 1217234 CUSIP 14167L103 13F (30d) 212 filings 208 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)